Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III everolimus plus octreotide LAR versus placebo plus octreotide LAR in advanced carcinoid tumor
2006-004507-18Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2006
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Carcinoid Tumor (CT) and neuroendocrine carcinoma (NEC) comparing RAD001 plus Sandostatin LAR with Placebo plus Sandostatin LAR (2 arms). Primary endpoint: progression-free survival. Started Nov 2006; status: completed.
02
Drugs
octreotideeverolimus
03
Conditions
Carcinoid Tumor (CT)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on 2006-004507-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004507-18.